Famous Patents
The first commercial microwave oven was nearly 6 feet tall and weighed in at 750 pounds.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6407255 | Chemical synthesis of 1,2,4-triazolinone derivative The present invention relates to a process for the preparation of morpholine derivatives of formula (I) which are useful as a therapeutic agents. ##STR1##... | 06/18/2002 |
| 6387388 | Pesticidal formulation The present invention is directed to a pesticidal composition of a water-soluble pesticide and processes for its manufacture. More specifically, the invention relates to a soluble granule (SG) pesticidal formulation comprising a water-soluble pesticide an... | 05/14/2002 |
| 6372764 | Pyrrolidine modulators of chemokine receptor activity The present invention is directed to pyrrolidine compounds of the formula I: ##STR1## (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine ... | 04/16/2002 |
| 6372754 | Spirocyclic ketones and their use as tachykinin antagonists The present invention relates compounds of the formula (I): ##STR1## wherein R1, R2, R3, R4 and R5 represent a variety of substituents; R6 represents hydrogen, CORa, CO2 R | 04/16/2002 |
| 6350915 | Process for the synthesis of 1-(3,5-bis(trifluoromethyl)-phenyl)ethan-1-one The present invention is concerned with a novel process for the preparation of 1-(3,5-bis(trifluromethyl)phenyl)ethan-1-one (CAS 30071-93-3). This compound is useful as an intermediate in the synthesis of therapeutic agents.... | 02/26/2002 |
| 6348330 | Method for measuring human neurokinin-3 receptor ligand binding A recombinant human neurokinin-3 receptor (hereinafter identified as human NK3R) is disclosed which has been prepared by polymerase chain reaction techniques. Also disclosed is the complete sequence of human NK3R complementary DNA; expression systems, inc... | 02/19/2002 |
| 6329401 | Enhancement of sleep with a tachykinin antagonist A tachykinin antagonist is useful, alone or in conjunction with other agents, for altering circadian rhythmicity and alleviating circadian rhythm disorders and for enhancing and improving the quality of sleep.... | 12/11/2001 |
| 6319953 | Treatment of depression and anxiety with fluoxetine and an NK-1 receptor antagonist The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and fluoxetine.... | 11/20/2001 |
| 6303593 | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity The present invention is directed to pyrrolidine compounds of the formula I: ##STR1## (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine ... | 10/16/2001 |
| 6297376 | Chemical synthesis of morpholine derivatives ##STR1## The present invention relates to a process for the preparation of mopholine derivatives of formula (I) which are useful as a therapeutic agents.... | 10/02/2001 |
| 6274604 | Alteration of circadian rhythmicity with a tachykinin antagonist A tachykinin antagonist is useful, alone or in conjunction with other agents, for altering circadian rhythmicity and alleviating circadian rhythm disorders and for enhancing and improving the quality of sleep.... | 08/14/2001 |
| 6271230 | Use of NK-1 receptor antagonists for treating cognitive disorders The present invention provides methods for the treatment or prevention of cognitive disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK... | 08/07/2001 |
| 6271347 | Eosinophil eotaxin receptor The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human ଲ-chemokine receptor and has been designated "CC CKR3". The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the e... | 08/07/2001 |
| 6258943 | Human neurokinin-3 receptor A recombinant human neurokinin-3 receptor (hereinafter identified as human NK3R) is disclosed which has been prepared by polymerase chain reaction techniques. Also disclosed is the complete sequence of human NK3R complementary DNA; expression systems, inc... | 07/10/2001 |
| 6255545 | Process for the synthesis of 3,5-bis(trifluoromethyl)-bromobenzene The present invention is concerned with a novel process for the preparation of 3,5-bis(trifluoromethyl)bromobenzene (CAS 328-70-1). This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.... | 07/03/2001 |
| 6255550 | Stabilization of the reagent dimethyl titanocene The present invention is directed to organic solutions of the reagent dimethyl titanocene which further comprise a sterically hindered ester and optionally titanocene dichloride. Stability of the reagent dimethyl titanocene is enhanced by the presence of ... | 07/03/2001 |
| 6235735 | Morpholine and thiomorpholine tachykinin receptor antagonists Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiov... | 05/22/2001 |
| 6232311 | Method for treating or preventing psychosomatic and psychoimmunologic disorders A tachykinin receptor antagonist is useful for treating or preventing a psychosomatic disorder in a patient.... | 05/15/2001 |
| 6229010 | Polymorphic form of a tachykinin receptor antagonist This invention is concerned with a novel polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)-ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist useful in t... | 05/08/2001 |
| 6225320 | Spiro-azacyclic derivatives and their use as therapeutic agents Substituted spiro-azacyclic derivatives of structural formula I are tachykinin receptor antagonists of use, for example, in the treatment of pain, inflammation, migraine, emesis and posttherpetic neuralgia ##STR1## Wherein A is a pyridyl, X is --CH2--, Y ... | 05/01/2001 |
| 6214846 | Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents The present invention relates to compounds of formula (I), wherein R1 represents a fluoroC1-2 alkoxy group; and R2 represents a hydrogen or halogen atom or a C1-4 alkyl, C1-4 alkoxy, fluoroC1-4 | 04/10/2001 |
| 6211174 | Naphtho-fused lactams promote release of growth hormone The present invention is directed to certain naphtho-fused lactams of the general structural formula: ##STR1## wherein and R1, R1a, R1b, R2a, R2b, R3a, R4, R5, R6... | 04/03/2001 |
| 6180624 | Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception This invention relates to methods and compositions for treating pain and nociception in a patient by administering a combination of a morpholine or thiomorpholine tachykinin antagonist and an opioid analgesic.... | 01/30/2001 |
| 6177564 | Process for the synthesis of N-benzyl-3-(4-fluorophenyl)-1-4-oxazin-2-one The present invention is concerned with a novel process for the preparation of N-benzyl-3-(4-fluorophenyl)-1,4-oxazin-2-one of the formula: ##STR1## This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological act... | 01/23/2001 |
| 6172077 | Spiro-azacyclic derivatives and their use as therapeutic agents The present invention is directed to substituted spiro-azacyclic derivatives of the formula (I): ##STR1## (wherein R1, R2, R3, R4, R5, R6, R9, R10, X, Y, p and q are d... | 01/09/2001 |
| 6166037 | Pyrrolidine and piperidine modulators of chemokine receptor activity The present invention is directed to pyrrolidine and piperidine compounds of the formula I: ##STR1## (wherein R1, R2, R3, R4a, R4b, R4c, R4d, R4e, R4f,... | 12/26/2000 |
| 6162805 | Use of an NK-1 receptor antagonist and an SSRI for treating obesity The present invention relates to the use of an NK-1 receptor antagonist and a selective serotonin reuptake inhibitor for the treatment or prevention of obesity.... | 12/19/2000 |
| 6156749 | Use of NK-1 receptor antagonists for treating movement disorders The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 antagonist for the manufacture of a medicament for oral administration for the treatment or prevention of movement disorders, methods of treatment using such a NK-... | 12/05/2000 |
| 6140349 | Cyclic amine modulators of chemokine receptor activity The present invention is directed to cyclic amines of the formula I: ##STR1## (wherein R1, R2, R3, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compou... | 10/31/2000 |
| 6140324 | Use of a tachykinin antagonist and a muscarinic antagonist and/or an antihistamine to treat motion sickness The present invention relates to the use of a tachykinin antagonist and a muscarinic antagonist and/or an antihistamine for the treatment or prevention of motion sickness. There is also provided pharmaceutical compositions and products comprising a tachyk... | 10/31/2000 |
| 6136827 | Cyclic amine modulations of chemokine receptor activity The present invention is directed to cyclic amines of the formula I: ##STR1## (wherein R1, R2, R3, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compou... | 10/24/2000 |
| 6136824 | 1-piperidinyl-propan-2-derivatives and their use as therapeutic agents The present invention relates compounds of the formula (I): ##STR1## wherein R1 and R2 each independently represents a phenyl group optionally substituted by a variety of substituents; R3 represents a variety of substituen... | 10/24/2000 |
| 6130331 | Chemical synthesis of a chiral 1,4-oxazin-2-one The present invention relates to a process for the preparation of substantially pure N-((S)-(-)--methylbenzyl)-3-(S)-(4-fluorophenyl)-1,4-oxazin-2-one hydrochloride, which comprises selectively crystallising the (S,S)-diastereomer as the hydro... | 10/10/2000 |
| 6127365 | Spiro-ketal derivatives and their use as therapeutic agents The present invention is directed to compounds of the formula (I): ##STR1## (wherein R1, R2, R3, R4, R5, R6, R9a, R9b, m and n are as defined herein) which are tachyki... | 10/03/2000 |
| 6123964 | Wet granulation formulation of a growth hormone secretagogue The present invention relates to a pharmaceutical composition and a process for the preparation of a tablet containing a growth hormone secretagogue as the active ingredient. The tablet is prepared by forming a powder blend of the active ingredient N... | 09/26/2000 |
| 6124319 | 3,3-disubstituted piperidines as modulators of chemokine receptor activity The present invention is directed to 3,3-disubstituted piperidines of the formula I: ##STR1## (wherein X, Y, Z, Ar, R, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are ... | 09/26/2000 |
| 6121325 | Naphthyl compounds promote release of growth hormone The present invention is directed to certain compounds of the general structural formula: ##STR1## wherein R1, R1a, R2a, R3, R3a, R4, R5, R6, A, W, and n are as d... | 09/19/2000 |
| 6121261 | Method for treating attention deficit disorder A tachykinin receptor antagonist is useful for treating or preventing attention deficit disorder, optionally associated with hyperactivity, in a patient.... | 09/19/2000 |
| 6117855 | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of CNS-penetrant NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.... | 09/12/2000 |
| 6114315 | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety The present invention provides methods for the treatment or prevention of major depressive disorder with anxiety without concomitant therapy with other anti-depressant or anti-anxiety agents which comprises oral administration of an orally active, long ac... | 09/05/2000 |
